FDA’s Woodcock to Head Office of Pharmaceutical Quality; New Details Emerge
This article was originally published in RPM Report
Executive Summary
FDA’s proposed Office of Pharmaceutical Quality will be initially headed by CDER Director Janet Woodcock. OPQ would hold responsibility over the manufacturing quality of a drug or biologics throughout a product’s lifecycle; eight offices will oversee activities from policy development to surveillance.